8

Home [health.maryland.gov] Flu Packet... · FIRST DOSE Place label here. First Dose First dose administered b SECOND DOSE Place label here. ... appointment reminders and other materials

Download PDF Report

Upload
others
View
1
Download
0

Embed Size (px)

Citation preview

Page 1: Home [health.maryland.gov] Flu Packet... · FIRST DOSE Place label here. First Dose First dose administered b SECOND DOSE Place label here. ... appointment reminders and other materials

Page 2: Home [health.maryland.gov] Flu Packet... · FIRST DOSE Place label here. First Dose First dose administered b SECOND DOSE Place label here. ... appointment reminders and other materials

Page 3: Home [health.maryland.gov] Flu Packet... · FIRST DOSE Place label here. First Dose First dose administered b SECOND DOSE Place label here. ... appointment reminders and other materials

Page 4: Home [health.maryland.gov] Flu Packet... · FIRST DOSE Place label here. First Dose First dose administered b SECOND DOSE Place label here. ... appointment reminders and other materials

Page 5: Home [health.maryland.gov] Flu Packet... · FIRST DOSE Place label here. First Dose First dose administered b SECOND DOSE Place label here. ... appointment reminders and other materials

Page 6: Home [health.maryland.gov] Flu Packet... · FIRST DOSE Place label here. First Dose First dose administered b SECOND DOSE Place label here. ... appointment reminders and other materials

Page 7: Home [health.maryland.gov] Flu Packet... · FIRST DOSE Place label here. First Dose First dose administered b SECOND DOSE Place label here. ... appointment reminders and other materials

Page 8: Home [health.maryland.gov] Flu Packet... · FIRST DOSE Place label here. First Dose First dose administered b SECOND DOSE Place label here. ... appointment reminders and other materials

ER Pharmacist Review of First Dose Non-Emergent Medications · ER Pharmacist Review of First Dose ... Use of the Omnicell system ... • Pharmacist review of first dose, non-emergent

ER Pharmacist Review of First Dose Non-Emergent Medications · ER Pharmacist Review of First Dose ... Use of the Omnicell system ... • Pharmacist review of first dose, non-emergent

Documents

A Phase 1, First-in-Human, Open-Label, Dose Escalation

A Phase 1, First-in-Human, Open-Label, Dose Escalation

Documents

Copy of First Human Dose

Copy of First Human Dose

Documents

A Single-Dose, Open-label, Randomized, Crossover, Drug ... › ProvidedDocs › 38 › NCT03100838 › Prot_SAP_000.pdfExperimental Design: A single-dose, randomized, open-label, drug-drug

A Single-Dose, Open-label, Randomized, Crossover, Drug ... › ProvidedDocs › 38 › NCT03100838 › Prot_SAP_000.pdfExperimental Design: A single-dose, randomized, open-label, drug-drug

Documents

Pharmacology-Guided Dose-Escalation of First-in-Class Drugs...Pharmacology-Guided Dose-Escalation of First-in-Class Drugs almorexant (ORX1/2-antagonist) and rimonabant (CB1-antagonist)

Pharmacology-Guided Dose-Escalation of First-in-Class Drugs...Pharmacology-Guided Dose-Escalation of First-in-Class Drugs almorexant (ORX1/2-antagonist) and rimonabant (CB1-antagonist)

Documents

US EPA - Read the Label First - Garden (Tagalog)

US EPA - Read the Label First - Garden (Tagalog)

Documents

PHASE 2B ASTEROID STUDY 12-MONTH TOPLINE RESULTS …€¦ · SETRUSUMAB (BPS804) –ASTEROID STUDY 6 Treatment Period = 12 months 28 day screening High dose open label High dose blinded

PHASE 2B ASTEROID STUDY 12-MONTH TOPLINE RESULTS …€¦ · SETRUSUMAB (BPS804) –ASTEROID STUDY 6 Treatment Period = 12 months 28 day screening High dose open label High dose blinded

Documents

Dasatinib, nilotinib and standard-dose imatinib for the first-line … · Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia:

Dasatinib, nilotinib and standard-dose imatinib for the first-line … · Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia:

Documents

Randomized, Open-label, Dose-finding, Phase 2 Study of ... · Pediatric Phase 2 Study Design (UX023-CL201) • Data available for first 36 subjects through 40 weeks Pre-specified

Randomized, Open-label, Dose-finding, Phase 2 Study of ... · Pediatric Phase 2 Study Design (UX023-CL201) • Data available for first 36 subjects through 40 weeks Pre-specified

Documents

Official Protocol Title: An Open-Label, Single-Dose …...Official Protocol Title: NCT number: NCT03108924 Document Date: 09-Jun-2017 An Open-Label, Single-Dose Study to Investigate

Official Protocol Title: An Open-Label, Single-Dose …...Official Protocol Title: NCT number: NCT03108924 Document Date: 09-Jun-2017 An Open-Label, Single-Dose Study to Investigate

Documents

Official Title: A Phase 1, Open-Label, Single -Dose

Official Title: A Phase 1, Open-Label, Single -Dose

Documents

Determination of the first dose for multispecific monoclonal … · 2017. 9. 17. · "Determination of the first dose for multispecific monoclonal antibodies: practical examples"

Determination of the first dose for multispecific monoclonal … · 2017. 9. 17. · "Determination of the first dose for multispecific monoclonal antibodies: practical examples"

Documents

karyotype, older age, and reduced first-line dose

karyotype, older age, and reduced first-line dose

Documents

First findings report - Energy Label Evaluation

First findings report - Energy Label Evaluation

Documents

Haemodynamic response and pharmacokinetics after the first dose

Haemodynamic response and pharmacokinetics after the first dose

Documents

US Food and Drug Admnistration · teaspoons of children's acetaminophen elixir because the label said to give one dose. Thinking that the dose cup held only one dose, she gave him

US Food and Drug Admnistration · teaspoons of children's acetaminophen elixir because the label said to give one dose. Thinking that the dose cup held only one dose, she gave him

Documents

A Phase 1, First-in-Human, Open-Label, Dose Escalation ......Jason J. Luke, MD, FACP @jasonlukemd A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, a Bispecific

A Phase 1, First-in-Human, Open-Label, Dose Escalation ......Jason J. Luke, MD, FACP @jasonlukemd A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, a Bispecific

Documents

A Phase 1, First-in-Human, Open-Label, Dose Escalation ......Treatment related SAEs (n=6) include Gr3 myocarditis, Gr3 enteritis, Gr3 enterocolitis, Gr2 arthralgia, Gr2 pneumonitis,

A Phase 1, First-in-Human, Open-Label, Dose Escalation ......Treatment related SAEs (n=6) include Gr3 myocarditis, Gr3 enteritis, Gr3 enterocolitis, Gr2 arthralgia, Gr2 pneumonitis,

Documents

A Phase 1, Multicenter, Open-Label, First-in-Human, Dose ... · 12/02/2014 · spasm, myalgia, gastrointestinal toxicities, increased liver enzymes, fatigue, dysgeusia, and alopecia

A Phase 1, Multicenter, Open-Label, First-in-Human, Dose ... · 12/02/2014 · spasm, myalgia, gastrointestinal toxicities, increased liver enzymes, fatigue, dysgeusia, and alopecia

Documents

An Open-Label, Multicenter Phase 1/2 Dose Escalation and ... · THOR-707 An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and

An Open-Label, Multicenter Phase 1/2 Dose Escalation and ... · THOR-707 An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and

Documents

First in Human dose

First in Human dose

Health & Medicine

High first dose quinine regimen for treating severe malaria

High first dose quinine regimen for treating severe malaria

Documents

NCT02431260 Phase 1/2, Open-Label, Dose-Escalation, Safety … · 2019. 1. 29. · 6

NCT02431260 Phase 1/2, Open-Label, Dose-Escalation, Safety … · 2019. 1. 29. · 6

Documents

Why Elimidrol? the First dose! - FTC

Why Elimidrol? the First dose! - FTC

Documents

First-In-Man High-Cumulative-Dose Mesenchymal Stem Cell

First-In-Man High-Cumulative-Dose Mesenchymal Stem Cell

Documents

A phase I, open-label, dose-escalation, multicenter study ... · A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myeloﬁbrosis

A phase I, open-label, dose-escalation, multicenter study ... · A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myeloﬁbrosis

Documents

A PHASE 1b, OPEN-LABEL, SINGLE-ARM, DOSE-SELECTION, …

A PHASE 1b, OPEN-LABEL, SINGLE-ARM, DOSE-SELECTION, …

Documents

PLEASE READ ENTIRE LABEL FIRST DISCLAIMER OF …

PLEASE READ ENTIRE LABEL FIRST DISCLAIMER OF …

Documents

Open‐Label, Multi‐Dose, Pilot Safety Study of Injection of

Open‐Label, Multi‐Dose, Pilot Safety Study of Injection of

Documents

First Dose and Dose Escalation - AGAH

First Dose and Dose Escalation - AGAH

Documents